Prakt. lékáren. 2021; 17(3): 150-152 | DOI: 10.36290/lek.2021.031

Intravitreal implants for the treatment of uveitides

Michaela Brichová
Oční klinika 1. LF UK a VFN, Praha

Intravitreal implants are used to treat uveitides either alone or in combination with systemic therapy. In the case of corticoid implants (dexamethasone, fluocinolone acetonide), they significantly reduce the need for systemic therapy and thus the frequency of side effects. Ganciclovir implant in cytomegalovirus retinitis eliminates the need for repeated intravitreal injections. The benefits of this form of treatment significantly outweigh the risk and severity of local side effects (cataract, glaucoma, retinal detachment).

Keywords: uveitis, intravitreal implant, dexamethasone, fluocinolone acetonide, ganciclovir.

Published: October 12, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Brichová M. Intravitreal implants for the treatment of uveitides. Praktické lékárenství. 2021;17(3):150-152. doi: 10.36290/lek.2021.031.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol 2005; 140(3): 509-516. Go to original source... Go to PubMed...
    2. Rothova A. Inflammatory cystoid macular edema. Curr Opin Ophthalmol. 2007; 18(6): 487-492. Go to original source... Go to PubMed...
    3. Barisani-Asenbauer T. Uveitis - a rare disease often associated with systemic diseases and infections - a systematic review of 2619 patients. Orphanet J Rare Dis. 2012; 7: 57. Go to original source... Go to PubMed...
    4. Iovino C, Mastropasqua R, Lupidi M, et al. Intravitreal dexamethasone implant as a sustained release drug delivery device for the treatment of ocular diseases: a comprehensive review of the literature. Pharmaceutics 2020; 12(8): 703. Go to original source... Go to PubMed...
    5. Wang K, Wang Y, Gao L, et al. Dexamethasone inhibits leukocyte accumulation and vascular permeability in retina of streptozotocin-induced diabetic rats via reducing vascular endothelial growth factor and intercellular adhesion molecule-1 expression. J. Biol Pharm Bull. 2008; 31(8): 1541-1546. Go to original source... Go to PubMed...
    6. Lowder C, Rubens Belfort Jr R, Lightman S, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 2011; 129(5): 545-553. Go to original source... Go to PubMed...
    7. Bodaghi B, Nguyen QD, Jaffe G, et al. Preventing relapse in non-infectious uveitis affecting the posterior segment of the eye - evaluating the 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN®). J Ophthalmic Inflamm Infect 2020; 10(1): 32. Go to original source... Go to PubMed...
    8. Jaffe GJ, Pavesio C. Effect of an fluocinolone acetonide insert on recurrence rates in noninfectious intermediate, posterior, or panuveitis: 3-year results. Ophthalmology. 2020; 127(10): 1395-1404. Go to original source... Go to PubMed...
    9. Meira J, Madeira C, Falcão-Reis F, et al. Sustained control from recurring non-infectious uveitic macular edema with 0.19 mg fluocinolone acetonide intravitreal implant - a case report. Ophthalmol Ther 2019; 8: 635-641. Go to original source... Go to PubMed...
    10. Musch DC, Martin DF, Gordon JF, et al. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. N Engl J Med 1997; 337(2): 83-90. Go to original source... Go to PubMed...
    11. Oktavec KC, Nolan K, Brown DM. Clinical outcomes in patients with cytomegalovirus retinitis treated with ganciclovir implant. Am J Ophthalmol 2012; 153: 728-733. Go to original source... Go to PubMed...

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.